Metabolism News and Research

Latest Metabolism News and Research

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta Pharmaceuticals Corp. announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2010

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced preliminary data from a single site participating in the multicenter Phase 2 clinical trial that showed that Positron Emission Tomography (PET) imaging with its novel investigational agent flurpiridaz F 18 injection (formerly known as BMS747158) provided better image quality than technetium-99m sestamibi single photon emission computed tomography (SPECT), the current standard for the non-invasive detection of coronary artery disease (CAD).

8 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 regulates inflammatory pathways, suggesting that it may effectively control inflammatory responses associated with autoimmune diseases and atherosclerosis.

7 Jun 2010

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Focusing on helping clinicians improve experiences for their patients, GE Healthcare is highlighting an innovative portfolio of molecular imaging technologies and agents at the 57th annual meeting of the Society of Nuclear Medicine, June 5-9, in Salt Lake City.

7 Jun 2010

Researchers one step closer to understand how activity outside of nucleus determines cell's behavior

With the rapid and continuous advances in biotechnology, scientists are better able to see inside the nucleus of a cell to unlock the secrets of its genetic material. However, what happens outside of the nucleus has, in many ways, remained a mystery. Now, researchers with the National Institutes of Health are closer to understanding how activity outside of the nucleus determines a cell's behavior.

5 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Roche's new dual-PCR target HIV-1 viral load test receives FDA approval

Roche Molecular Diagnostics announced today that the Food and Drug Administration (FDA) approved its new dual-PCR target HIV-1 viral load test to quantify the amount of virus in a patient's blood. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 is the first quantitative viral load test to amplify and detect two separate regions of a target genome and offers a fully automated and reliable solution for physicians to make informed treatment decisions for HIV-1 patients undergoing antiretroviral therapy.

4 Jun 2010

Researchers generate the first comprehensive genetic parts list of mouse hypothalamus

A Johns Hopkins and Japanese research team has generated the first comprehensive genetic "parts" list of a mouse hypothalamus, an enigmatic region of the brain — roughly cherry-sized, in humans — that controls hunger, thirst, fatigue, body temperature, wake-sleep cycles and links the central nervous system to control of hormone levels.

4 Jun 2010

Key regulator of fat cell differentiation identified

New research led by UCD Conway Fellow, Professor Johan Ericsson has identified a key regulator of fat cell differentiation that may be a novel target for obesity drugs. The results of the research are published in the current edition of the scientific journal, Proceedings of the National Academy of Sciences (PNAS).

4 Jun 2010

Study provides personalized strategies to boost AIAA compliance in breast cancer patients

Aromatase inhibitor-associated arthralgia (AIAA) is a major side effect in breast cancer survivors, producing joint pain so severe that as many as ten percent of women discontinue their therapy prematurely while undergoing treatment with these lifesaving drugs.

3 Jun 2010

Research may yield new urine test to diagnose autism

Children with autism have a different chemical fingerprint in their urine than non-autistic children, according to new research published tomorrow in the print edition of the Journal of Proteome Research.

3 Jun 2010

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Novartis Pharmaceuticals Corporation announced today that a Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors.

3 Jun 2010

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Entelos, Inc. has announced a publication in the peer-reviewed journal Clinical and Experimental Immunology describing the Type 1 Diabetes (T1D) PhysioLab® platform, an in silico solution for rapidly streamlining preclinical research through the evaluation of alternative scenarios for therapeutic strategies.

2 Jun 2010

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

EntreMed, Inc., today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research (Vol. 16, Issue 11).

2 Jun 2010

Genes influence AIAA side effect in breast cancer survivors

2 Jun 2010

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.

2 Jun 2010

Juvenile Diabetes Research Foundation International honors Roche with "Chancellor's Award"

Roche, makers of ACCU-CHEK® blood glucose meters, infusion pumps, lancing devices and data management systems for people with diabetes, received the Juvenile Diabetes Research Foundation International's "Chancellor's Award" during the JDRF Annual Conference in Washington, D.C. The "Chancellor's Award" recognizes and honors longstanding JDRF corporate partners.

From Roche Sequencing and Life Science 2 Jun 2010

Postdoctoral scientists receive NYSCF-Druckenmiller Fellowship award

The New York Stem Cell Foundation (NYSCF) today announced the award of eight new NYSCF-Druckenmiller Fellows. These postdoctoral scientists join 15 accomplished stem cell researchers from leading institutions who have been supported by the program since 2006. NYSCF has awarded 23 fellowships to date.

2 Jun 2010

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.

2 Jun 2010

Metabolism News and Research

Latest Metabolism News and Research

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Researchers one step closer to understand how activity outside of nucleus determines cell's behavior

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Roche's new dual-PCR target HIV-1 viral load test receives FDA approval

Researchers generate the first comprehensive genetic parts list of mouse hypothalamus

Key regulator of fat cell differentiation identified

Study provides personalized strategies to boost AIAA compliance in breast cancer patients

Research may yield new urine test to diagnose autism

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

Genes influence AIAA side effect in breast cancer survivors

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

Juvenile Diabetes Research Foundation International honors Roche with "Chancellor's Award"

Postdoctoral scientists receive NYSCF-Druckenmiller Fellowship award

FDA accepts Orexigen's Contrave NDA for treatment of obesity

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep